Features of drug pharmacotherapy in patients with heart failure after pacemaker implantation

Abstract

Over the past decades, an increase in mortality from chronic heart failure (CHF) has been recorded, for the treatment of which the implantation of an electrocardiostimulator can be used. The medical support of the patient with a pacemaker was optimized depending on the functional class (FC) of CHF. An increase in both the frequency of prescription and the dose of (3-adrenergic receptor blockers with an increase in the FC of CHF in patients with CHF at a one-year follow-up period after implantation of pacemakers was shown. This not only improves myocardial contractility, but also reduces the risk of complications of pacing. Patients with implanted pacemakers require careful titration of medications taking into account the FC of CHF, especially with regard to its high FC, primarily for therapy with angiotensin-converting enzyme inhibitors, antiplatelet agents, and antiarrhythmic drugs. Keywords: chronic heart failure, pacemaker implantation, drug therapy.